Professional Experience/ Research Work of Dr Zirvi

1993 -2000     

Lab Manager and Tech. Supervisor, Molecular Medicine, Inc., 95 E Main Street, Denville, NJ

Testing of human serum specimens for allergen specific IgE, 'Total IgE, T4, T-Uptake and TSH levels. Day to day running of the Laboratory and keeping of the lab data and other information up to date for NJ, NY States and Federal inspections.

1982 - 1993

Associate Professor, Dental Research Center, UMDNJ, NJ Dental School, 110 Bergen Street, Newark, NJ 07103 (1989-93); Adjunct Assistant Professor (1982-87), Associate Professor (Co-terminus, 1988-93), Department of Surgery, UMDNJ-NJ Medical School, 185 So. Orange Avenue, Newark, NJ; Research Chemist, East Orange VA Medical Center (1982-89).

Experimental models for cancer chemotherapeutic drug testing and drugs against metastasis. Study of cancer chemotherapeutic agents against human tumor biop.sy specimens using in vitro and in vivo systems.

1981 – 1982

NRSA Fellow, Departments of Biochemistry/Chemistry, Vanderbilt Univ., Nashville, TN Cytochrome P-450 inhibition of cyclopropyl amines in in-vitro system.

1979-1981

NRSA Fellow, Cancer Center, U.C.S.D., La Jolla, CA

Development of in vitro model system for cancer chemotherapeutic studies.

1978 - 1979

Visiting Scientist, Department of Pharmacology, University of Louisville, Louisville, KY

Synthesis of pharmacologically active compounds

1972-1978      

Associate Professor, Department of Pharmacology, Shiraz University, Shiraz, Iran.

Study of chemistry and pharmacology of Iranian Medicinal plants. Teaching Pharmacology to Medical and dental students.

1969 – 1972

Senior Research Officer, Pakistan Council of Scientific. & Industrial Research Labs, Peshawar, Pakistan.

Study of medicinal plants. Isolation of pharmacologically active compounds.

 

                                               Research Accomplishments

a) US Patent

C. H. Jarboe and K. Zirvi

Certain N-substituted Cyclobutanecarboxamides, as Muscle Relaxant with Lessened Side-effects, U. S. Patent: 34,84,001, June, 1971.

 

b) Experimental Cancer Chemotherapy, Biochemistry and Metastasis Research 

 

Publications

  1. Enhancement of gastric mucus phospholipid secretion by an antiulcer agent, ebrotidine., Slomiany BL, Piotrowski E, Piotrowski J, Zirvi KA, Liau YH, Murty VL, Slomiany A., Gen Pharmacol. 1994 Sep. 25(5):1033-7
  2. Shah, V., Kumar, S. and Zirvi, K.A.: Metastasis of human colon tumor cells in vivo: correlation with the overexpression of plasminogen activators and 72 kDa gelatinasw. In Vivo. 8: 321-326, 1994.
  3. J.P. Keogh. K.A. Zirvi, S. Vossough, A. Slomiany and B.L. Slomiany. Pharmacological alterations of cellular transglutaminase activity and invasiveness in human colorectal carcinoma cells. Cancer Biochem Biophys 13:209‑220 (1993)
  4. Zirvi, K.A., Najjar, T.A. and Slomiany, B.L.: Sensitivity of human colon tumor metastases to anticancer drugs in athymic (nude) mice. Cancer Letters. 72: 39-44, 1993.
  5.  Zirvi, K.A., Keogh, J.P., Slomiany, A. and Slomiany, B.L.: Effects of exogenous transglutaminase on spreading of human colorectal carcinoma cells. Cancer Biochem Biophys. 13: 283-293,1993.
  6. ​Keogh, J.P., Zirvi, KA, Vossough, S., Slomiany, A. and Slomiany, B.L.: Pharmacological alterations of cellular transglutaminase activity and invasiveness in human colorectal carcinoma cells. Cancer Biochem Biophys. 13: 209-220, 1993.
  7. Zirvi, K.A., Keogh J.P. and Slomiany B.L.: Transglutaminase Activity in Human Colorectal Carcinomas of Differing Metastatic Potential. Cancer Letters 60: 85-92, 1991.
  8. Zirvi, K.: Development of Serum-free Media for the Growth of Human Gastrointestinal Adenocarcinoma Xenografts as Primary Tissue Cultures. J cancer Res & Clin Oncol (117: ‚ 1991.)
  9. Zirvi, K. and Grimmond, H.: Proteins Secreted by Caco-2 Cells Support growth of other Tumor Cells in Chee's Essential Medium Without Supplements. Cancer Biochem. & Biophys. 12:137-151, 1991.
  10. Zirvi, K.A. and Atabek, U.: In vitro Response of a Human Colon Tumor Xenograft and a Lung Adenocarcinoma Cell Line to a- difluoromethylornithine Alone and in Combination with 5Fluorouracil and Doxorubicin. J. Surgical Oncol. 48: 34-38, 1991.
  11. Hu, J., Zirvi, K. and Lee, M.: Combined Effect of pH and Sodium Cyanate on the Inhibition of Tumor Cell Proliferation and Metabolism by BCNU and Hyperthermia. Cancer Chemother. and Pharmacol. 26:269-272, 1990.
  12. Sidhu, MX, Russo, M.S., Zirvi, KA, Scala, L. and Kumar, S.: Tumorigenicity of EJ-ras Oncogen Transformed NIH 3T3 Cells and Expression of Plasminogen Activators. Cell Biol. mtl. Rep. 14:527-542, 1990.   
  13. Grimmond, H., Hill, G. and Zirvi, K.: Proteins Excreted by Primary Human Colon Carcinoma Cells (SW 480) Promote Spreading and Growth ofMetastatic Human Colon Carcinoma Cells (SW 620) in serum-free Medium. Cancer Biochem. and Biophys. 10:353-364, 1989 
  14. Zirvi, K.A., Dasmahapatra, K.S., Atabek, U. and Lyons, M.: Alpha difluoromethylornithine (DFMO) Inhibits Liver Metastasis Produced by Intrasplenic Injection of Human Tumor Cells Into Nude Mice. Experimental and Clinical Metastasis 7:591-598, 1989.
  15. Hu, J.J., Dimaira, M.J., Zirvi, K.A., Dikdan, G. and Lea, M.A.: Influence ofpH on the Modification of Thiols by Carbamoylating Agents and Effects on Glutathione Levels in Normal and Neoplastic Cells. Cancer Chemother. and Pharmacol. 24:95-101, 1989
  16. Hu, J.J., Zirvi, K.A. and Lea, M.A.: Interrelationship Between Sodium Cyanate and pH in the Regulation of Tumor Cell Division. Cancer Biochem. and Biophys. 10:269-274, 1989
  17.  Hu, J.J., Luke, A., Chellani, M., Zirvi, K.A. and Lea, M.A.: pH- Related Effects of Sodium Cyanate on Macromolecular Synthesis and Tumor Cell Division. Biochem. Pharmacol. 37-2259-2266, 1988.
  18. Zirvi, K. and Hill, G.J: Comparison of Growth and Drug-response of Human Tumor Cells in Serum-free and Serum- supplemented Media in Human Tumor-Clonogenic Assay. J. Surg. Oncol. 38:88-93, 1988.
  19. Grimmond, H.E. and Zirvi, K.A.:      Biochemical Analysis of the Effects of 1,3-Bis(2-Chlorthyl)-1-Nitrosourea on the Growth of a Human Melanoma Cell Line. Cancer Letters 36:131-137,1987.
  20. Hill, G., Zirvi, K., Hill, H. and Raina, S.: Advances in Cancer: Chemosensitivity Testing with Antineoplastic Agents. New Jersey Medicine 84:437-441, 1987.
  21. Zirvi, K., van der Bosch, J., Masui, H., Kaplan, N.O. and Hill, G.J.: Activity of Cancer Chemotherapeutic Agents against Human Colorectal Carcinoma grown as Primary Tissue Culture. J. Cancer Res. & Clin. Oncol. 113:20-26, 1987.
  22. Grimmond, H.E., Zirvi, K.A. and Hill, G.J.: Comparative Analysis of Cellular and Extracellular Proteins secreted by Two Human Tumor Cell Lines. Cancer Invest. 5:321-327, 1987.
  23. Zirvi, K., Chee, D.O. and Hill, G.J.: Continuous Growth of Human Tumor Cell Lines in Serum-free Media. In Vitro 22:369-374, 1986.
  24. Zirvi, K., Hill, G.J. and Hill, H.Z.: Comparative Studies of Chemotherapy of Human Cells in vitro by Tritiated Thymidine Uptake Inhibition and Soft Agar Clonogenic Assay. J. Surg. Oncol. 31:123-126,1986.
  25. Zirvi, K., Gilani, S.H. and Hill, G.J.: Embryotoxic Effects of Doxorubicin and N-trifluoroacetyladriamycin-14-valerate. Teratology 31:247-252, 1985.
  26. Zirvi, K., Masui, H., Giuliani, F. and Kaplan, N.: Correlation of Drug Sensitivity of Human Colorectal Carcinoma Cells Grown in Soft Agar and in Nude Mice. Int. J. Cancer 32:45- 51, 1983.
  27. Zirvi, K., van der Bosch, J. and Kaplan, N.O.: In Vitro Response of Nude-mouse-xenografted Human Colon Carcinoma. Cancer Res. 42:3789-3792, 1982.
  28. van der Bosch, J. and Zirvi, K.: Growth-state-specific Action of Interferon and 4'-deoxydoxorubicin in Primary Tissue Cultures of a Nude mouse-xenografted Human Colon Carcinoma. Cancer Res. 42:3793-3797, 1982.
  29. Giuliani, F.C., Zirvi, K. and Kaplan, N.O.: Therapeutic response of Human Tumor Xenografts in Athymic Mice to Doxorubicin. Cancer Res. 41:325-335, 1981.
  30.  Giuliani, F.C., Zirvi, K., Kaplan, N. 0. and Goldin, A.: Comparative Antineoplastic activity of N-Trifluoroacetyladriamycin- 1 4-valerate and Doxorubicin Against Human Tumors Xenografted into Athymic Mice. P. Petiti and G. G. Grassi (eds.), In: Current Chemotherapy and Immunotherapy, Vol. II, pp 1435-1436, The American Society for Microbiology, Washington, D. C., U.S.A., 1981.

 

b. Book Chapters and Reviews

 

31. MacDonald, T.L., Zirvi, K., Burka, L.T., Peyman, P. and Guengerich, F.P.: Mechanism of Cytochrome P-450 Inhibition by Cyclopropyl Amines. J. Amer. Chem. Soc. 104:2050-2052, 1982.

32. .Leudke, D., Krishan, A., Chee, D., Carey, F., Chang, B., Franco, R., Johns, M., Kenady, D. and Zirvi, K.: Interlaboratory Reproducibility of the Human Tumor Colony-forming Assay (HTCFA): The Southern Cancer Study Group Experience, S. E. Salmon and J. M. Trent (eds.), In: Human Tumor Cloning, pp. 245-253, Miami: Grune & Stratton, 1984.

33. MacDonald, T.L., Zirvi, K., Burka, L.T., Peyman, P. and Guengerich, F.P.: Mechanism of Cytochrome P-450 Inhibition by Cyclopropyl Amines. J. Amer. Chem. Soc. 104:2050-2052, 1982.

34. Zirvi, K. and Fakouhi, t.: Synthesis and Neuropharmacology of Butyrylureas. Il Fannaco 37:335-342, 1982.

35  Zirvi, K. and Fakouhi, T.: Synthesis and Neuropharmacology of Cyclobutanecarbonylureas. Il Farmaco 34:170-177, 1979

37. Zirvi, K., Ikaram, M., Dar, M.S., Fakouhi, T. and Erker, E.T.: Chemical and Pharmacological Screening of Iranian Medicinal Plants. Fitoterapia 49:213-220, 1978.

39. Zirvi, K. and Fakouhi, T.: Synthesis and Neuropharmacology of Cyclopropanecarbonylureas. II Farmaco 33:288-294, 1978.

41. Zirvi, K. and Fakouhi, T.: Some Aspects of the Neuropharmaco1og' of Phenylurea.   Arzneimittel-Forschung 27:1194-1198, 1977.

43. Zirvi, K.: IR Spectral Characteristics ofNon-Clycic Diacylamides II. Spectrochim. Act. 32Am: 1215-1217,1976.

45. Tin-Wa, M., Fansworth, N.A. and Zirvi, K.: Sinoacutine from Glaucium contortuplicatum Boiss, J. Pharm. Sci. 65:755, 1976.

47. Zirvi, K., Dar, M. S. and Fakouhi, T.: The Biochemorphology of Cyclobutanecarbonylureas. J. Pharm. Sci. 65:649-651, 1974.

49. Zirvi, K., Miana, G.A., Jehangir, S. and Ghaznevi, 1.: Constituents of H. guadriloculare. Phytochemist 11:23491972.

51. Zirvi, K. and Jarboe, C.H.: IR Spectral Characteristics of Cyclobutane Ring System. J. Chem. Soc. (B) 1602-1606, 1971.

53. Zirvi, K. and Jarboe, C.H.: The Biochemorphology of Cyclobutanecarboximides. J. Med. Chem. 12:923-925,1969.

55. Zirvi, K. and Jarboe, C.H.: The Biochemorphology of Cyclobutanecarboxamides. J. Med. Chem. 12:926,1969.

57. Jarboe, C., Zirvi, K., Schmidt, C., McLafferty, F. and Haddon, W.: 1-Methyl-2,3-dibutylhemimellitate, a Unique Component of V. prunifolium. J. Org. Chem. 34:4202-4203,1969. 57.         

59. Zirvi, K. and Jarboe, C.H.: Diimides of Cyclobutane-1,1- dicarboxylic Acid. J. Med. Chem. 11, 183, 1968.

61. Jarboe, C.H., Zirvi, K., Nicholson, J.A. and Schmidt, C.M.: Scopoletin, an Antispasmodic Component of V. opulus and V. prunifolium. J. Med. Chem. 10:488-489, 1967.

63.Jarboe, C.H., Schmidt, C.M., Nicholson, J.A. and Zirvi, K.: Uterine Relaxant Properties of Viburnum. Nature212:837, 1966.

64. Guengerich, F., MacDonald, T., Burka, L., Miller, R., Liebler, D., Zirvi, K., Frederick, C., Kadlubar,F. and Prough, R.: Diversified Functions of Cytochrome P-450. E. Heitanen, M. Laitenen and 0. Hanninen (eds.). In: Cytochrome P-450, Biochem., Biophys. and Environmental Implications. pp. 27-34, Findland: Elsevier, 1982.

65. Jarboe, C., Zirvi, K. and Schmidt, C.: Infra-red Spectra of Ten New N-acylated Cyclobutanecarboxamides, "Sadtler Standard Spectra", Sadtler Research Labs, Inc., Philadelphia, PA, 1971, Supplement, pp. 39001-39010.

66. Ikram, M. and Zirvi, K.: Chemistry and Pharmacology of Glycyrrhiza glabra. Herba Polonica 22:312320, 1976.

67. Zirvi, K. and Ikram, M.: Alkaloids of some of the plants of Compositae. Pak J. Sci. & Ind. Res. 18:93-115, 1975.Research Expertise

 

Honors and Awards      

  1. International Cancer Research Technology Transfer (ICRETT) Award: To do research at Deutsche Krebsforchungszentrum Heidelberg, Heidelberg, Germany (March-April, 1978).
  2. Ph.D. - Graduate Dean's Honor Award (1965-68).
  3. University of Louisville, KY Research Fellowship Award, 1964.
  4. Fulbright-Hay's Award, 1964.

Membership before retirement

  1. American Association of Cancer Research.
  2.  American Society for Advancement of Science.
  3.  Metastasis Research Society.

Miscellaneous Activities

  1. Coordinator, "Cancer Research Colloquium", weekly seminar series, sponsored by Department of Surgery, NJ Medical School and New Jersey Cancer Center, 1983-93.
  2. Coordinator of Seminar Series for Medical students involved in cancer research, 1984-86.

Education

Ph.D.:  Pharmacology, University of Louisville, Louisville, KY., 1968.

M. Sc.: (Chemistry) Karachi University, Karachi, Pakistan, 1963.

B.Ed.     Central Training College, Punjab University, Lahore, 1961

B.Sc.     T. I. College, Rabwah, Pakistan, 1959